Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial

Journal of Hypertension
Lisa KurlandLars Lind

Abstract

Our aim was to determine if gene polymorphisms in the renin-angiotensin-aldosterone system (RAAS) were related to the degree of change in left ventricular hypertrophy (LVH) during antihypertensive treatment. Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months. The angiotensinogen T174M and M235T, the angiotensin-converting enzyme I/D, the AT1-receptor A1166C and the aldosterone synthase (CYP11B2) -344 C/T polymorphisms were analysed and related to the change in left ventricular mass (LVM). Patients with the angiotensinogen 174 TM genotype treated with irbesartan responded with the greatest reduction in LVM (-23 +/- 31SD g/m2 for TM and +0.5 +/- 18 g/m2 for TT, P = 0.005), independent of blood pressure reduction. Both the angiotensinogen 235 T-allele (P = 0.02) and the AT1-receptor 1166 AC genotype responded with the greatest reduction in LVM when treated with irbesartan (-0.1 +/- 19 g/m2 for AA and -18 +/- 30 g/m2 for AC, P = 0.02), independent of blood pressure redu...Continue Reading

References

Oct 2, 1992·Cell·X JeunemaitreJ M Lalouel
Feb 15, 1986·The American Journal of Cardiology·R B DevereuxN Reichek
Jun 9, 1994·The New England Journal of Medicine·M CaulfieldA J Clark
Oct 1, 1993·PCR Methods and Applications·V ShanmugamB K Saha
Apr 29, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R E SchmiederP Martus
Apr 1, 1999·Journal of Hypertension·J A StaessenR Fagard
May 20, 1999·Journal of the American College of Cardiology·H SchunkertH W Hense
Jan 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·P ParadisM Nemer
Jul 11, 2000·Journal of Molecular and Cellular Cardiology·P Lijnen, V Petrov
Jun 14, 2001·Journal of Hypertension·K MalmqvistJ Ostergern
Oct 11, 2001·Journal of Hypertension·L KurlandUNKNOWN Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial

❮ Previous
Next ❯

Citations

Feb 20, 2004·Current Hypertension Reports·Reinhold Kreutz
Jun 19, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Roberto TrottaLicia Iacoviello
Jun 7, 2005·Seminars in Dialysis·Madhumathi RaoUNKNOWN DialGene Consortium
Jan 20, 2005·Heart·Thomas Kahan, Lennart Bergfeldt
May 18, 2011·Circulation·Seema MitalUNKNOWN Pediatric Heart Network Investigators
May 31, 2011·Pharmacogenomics·Stefanie Klenke, Winfried Siffert
Feb 20, 2004·Current Hypertension Reports·Donna K ArnettUlrich Broeckel
Feb 3, 2005·Current Hypertension Reports·Stephen T Turner, Gary L Schwartz
Jun 5, 2007·Pharmacotherapy·Jaekyu Shin, Julie A Johnson
Nov 18, 2008·Advances in Genetics·Diddahally R GovindarajuEmelia J Benjamin
Nov 5, 2016·Pharmacogenomics·Fannie MottetSimon de Denus
Jul 3, 2008·The Annals of Pharmacotherapy·Simon de DenusMichel White
Nov 14, 2003·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Paul N Hopkins, Steven C Hunt
Apr 28, 2018·Pharmacogenomics·Simon de DenusUNKNOWN CANDIID II investigators
Aug 10, 2005·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Peter Karl Jacobsen
Mar 10, 2011·Journal of Cardiovascular Pharmacology·Henk VisscherBruce C Carleton
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Bernard Waeber, Michel Burnier
May 3, 2005·Pharmacogenetics and Genomics·Anke-Hilse Maitland-van der ZeeEric Boerwinkle
Nov 5, 2005·Journal of Hypertension·Jean-Brice MarteauSophie Visvikis-Siest
Dec 14, 2012·Expert Review of Clinical Pharmacology·Murielle Bochud, Idris Guessous
Dec 17, 2008·Pharmacological Reviews·Dieter Rosskopf, Martin C Michel
Mar 23, 2002·Journal of Hypertension·Robert H Fagard, Tatiana Kuznetsova
Sep 12, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Lijuan WangShaojun Wen
Jul 1, 2009·Personalized Medicine·Mona FiuzatChristopher M O'Connor
Oct 22, 2003·Journal of the American Society of Nephrology : JASN·Peter JacobsenHans-Henrik Parving
Jan 9, 2003·Pharmacogenomics·Stephen T Turner, Eric Boerwinkle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.